This site is for US healthcare professionals to provide online access to current, accurate, scientific information about our products. It is prepared by Janssen Medical Information and is not intended for promotional purposes, nor for medical advice.

  1. Home
  2. Announcements
  3. Selected Announcement

Neuroscience Conferences

Janssen-sponsored congress materials from select Neuroscience Conferences:

 

Data presented at the 2021 Neuroscience Education Institute Annual Meeting

 

https://www.neiglobal.com/VSP/NEIVSPSummary/tabid/561/Default.aspx or contact us by visiting askjanssenmedinfo.com or by calling 1-800-JANSSEN (1-800-526-7736).

Poster titles

  • Long-Term Safety of Esketamine Nasal Spray in Adults with Treatment-Resistant Depression: A Subgroup Analysis of the Ongoing SUSTAIN-3 Study
  • Long-Term Efficacy of Esketamine Nasal Spray in Adults with Treatment-Resistant Depression: A Subgroup Analysis of the Ongoing SUSTAIN-3 Study
  • Long-term Safety and Sustenance of Response with Esketamine Nasal Spray in Patients with Treatment-Resistant Depression: SUSTAIN-3 Interim Results (Encore)
  • Real-World Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression who Re-initiated Esketamine After Initial Treatment
  • Impact of Rapid Antidepressant Therapy on Patient-Centered Outcomes in Adults with Major Depressive Disorder and Active Suicidal Ideation With Intent
  • A Meta-Analysis of Esketamine Nasal Spray and Atypical Antipsychotic Antidepressant Responses in Pivotal Phase 3 Trials
  • Effect of Paliperidone Palmitate Versus Oral Antipsychotics on Treatment Failure in the Black/African American Subpopulation of the DREaM Study
  • COVID-19 Vaccination Attitudes Among Prescribers of Long-Acting Injectable Antipsychotics for Schizophrenia in the US and Their Patients: A Survey
  • Changes in Prescribing of Long-Acting Injectable Antipsychotics for Schizophrenia and Patient Outcomes During COVID-19 Pandemic: US Prescriber Survey

 

Data presented at the 2021 Psych Congress Annual Meeting

Please refer to the Psych Congress website directly for oral presentations and posters available for registered attendees at: https://virtual.psychcongress.com/ or contact us by visiting askjanssenmedinfo.com or by calling 1-800-JANSSEN (1-800-526-7736).

Poster titles

  • Long-term Safety and Sustenance of Response with Esketamine Nasal Spray in Patients with Treatment-Resistant Depression: SUSTAIN-3 Interim Results
  • Sleep Disturbance and Efficacy of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression: Findings from Randomized, Controlled Trials
  • Effects of Esketamine Nasal Spray on Depressive Symptom Severity in Adults with Treatment-Resistant Depression as Measured by the 9-Item Patient Health Questionnaire
  • Real-World Use of Esketamine Nasal Spray for Treatment-Resistant Depression at 22 Months: Characterizing Healthcare Settings, Prescribers, Pharmacies, Patients, and Key Safety Data
  • Indirect comparison estimating the benefit of esketamine compared with real-world treatment of treatment resistant depression in general psychiatry
  • Indirect comparison estimating the benefit of esketamine compared with distinct real-world treatment strategies for treatment resistant depression in general psychiatry
  • Real-world use of Esketamine Nasal Spray Among Commercially Insured Patients with Treatment-Resistant Depression
  • Access and Real-world Use Patterns of Esketamine Nasal Spray Among Patients with Treatment-Resistant Depression Covered by Private or Public Insurance
  • A Qualitative Analysis of Operational Efficiencies Associated with SPRAVATO® Therapy among Established Outpatient Treatment Centers in the United States
  • The Impact of Implementing Standardized Universal Acute Care Suicide Screening on Detection of Suicidality and Receipt of Subsequent Psychiatric Care
  • Suicide Screening, Detection, and Subsequent Care Patterns in a Large Health Care System’s Ambulatory Clinics and Hospitals
  • Development and Validation of Models to Predict High-Cost and High-Risk Events among Individuals with Major Depressive Disorder
  • Among US Adults with Major Depressive Disorder, Higher Severity of Insomnia Symptoms Is Independently Associated with Poorer Clinical, Economic, and Humanistic Outcomes
  • The Clinical, Economic and Humanistic Burden of Adults with Major Depressive Disorder with Moderate or Severe Insomnia Symptoms in the United States
  • A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6 Month Formulation
  • Relapse in Adequately Versus Not Adequately Treated Patients with Schizophrenia Transitioned to Paliperidone Palmitate 3-Month Injections: A Retrospective, Health Claims Database Analysis
  • Overall and Subgroup Analyses of Healthcare Resource Use and Costs for Participants Diagnosed with Recent-Onset Schizophrenia in the Disease Recovery Evaluation and Modification (DREaM) Trial
  • The Budget Impact of Introducing Once-Every-6-Months Paliperidone Palmitate for the Management of Schizophrenia in the United States
  • Long-acting Injectable Antipsychotic Utilization and Healthcare Costs Among Adult Medicaid Beneficiaries in South Carolina
  • Social Determinants of Health and Related Policies Impacting Adults with Schizophrenia in the United States
  • Adherence and Readmissions Associated with Paliperidone Palmitate 1- and 3-month versus Oral Antipsychotic Agent Treatment Switches Among Adult Medicaid Members Diagnosed with Schizophrenia
  • Cost Drivers and Economic Burden of Disease Relapse Episodes: The Experience of Stable Versus Relapsed Patients with Schizophrenia in Medicaid
  • A Comparison of Clinical Outcomes in Medicaid Beneficiaries with Schizophrenia Following Different Long-Acting Injectable Antipsychotic Sequencing Strategies
  • A Systematic Literature Review of Schizophrenia Clinical Practice Guidelines: Recommendations on Antipsychotic Treatment of First-episode Schizophrenia
  • Understanding Characteristics of Healthcare Providers with Higher-Than-Average Rates of Prescribing Long-Acting Injectable Antipsychotics: A US Healthcare Provider Survey
  • Perspectives on Prescribing Long-Acting Injectable Antipsychotics in the United States: A Healthcare Provider Survey
  • Changes in Prescribing Habits for Long-Acting Injectable Antipsychotics in the United States Due to the COVID-19 Pandemic: Results from a Healthcare Provider Survey
  • Increase in COVID-19 Infections Among Individuals with Schizophrenia in the United States and the Impact of Race/Ethnicity

Data presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2021

Please contact us directly to request posters presented at this meeting by visiting askjanssenmedinfo.com or by calling 1-800-JANSSEN (1-800-526-7736)

  • Differences in expected number of clinical management events before and during treatment with sphingosine-1-phosphate receptor modulators for multiple sclerosis
  • Fatigue evolution for patients without relapses on the FSIQ-RMS Symptoms Domain
  • A real-world study characterizing symptoms and impacts of fatigue in US adults with relapsing multiple sclerosis using a novel disease specific scale
  • Assessment of Composite Confirmed Disability Accumulation of ponesimod relative to teriflunomide on Progression Independent of Relapse Activity in the OPTIMUM Phase 3 study
  • Assessing the Impact of Disease Activity and Fatigue Symptom on Work Productivity and Activity Impairment in Patients with Relapsing Multiple Sclerosis
  • Evaluating the Impact of Fatigue Symptoms on Work Productivity and Activity Impairment using Longitudinal data rom Phase III OPTIMUM study
  • MS Fatigue: Treatment effect of ponesimod in RMS patients with and without disease activity
  • Identifying and Characterizing Fatigue in Patients Diagnosed with Multiple Sclerosis on Disease-Modifying Therapies Using Real World Evidence

 

Data presented at the 2021 Academy of Managed Care Pharmacy Nexus Conference

Contact us by visiting askjanssenmedinfo.com or by calling 1-800-JANSSEN (1-800-526-7736).

Poster titles

  • Analysis of Healthcare Resource Utilization and Costs for Participants Diagnosed with Recent-Onset Schizophrenia in the Disease Recovery Evaluation and Modification (DREaM) Trial
  • Predictors of 30-Day Readmissions and Costs Among Adult Medicaid Beneficiaries with Schizophrenia or Schizoaffective Disorder Utilizing 1-Month or 3-Month Paliperidone Palmitate or Requiring a Switch in Oral Antipsychotic Agent

Data presented at the 37th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) 2021

Please contact us directly to request posters presented at this meeting by visiting askjanssenmedinfo.com or by calling 1-800-JANSSEN (1-800-526-7736)

  • Ponesimod shows improved effect on brain volume compared with other DMTs, a model based meta-analysis
  • Relationship between brain volume and disability, cognition, motor function, and MS-fatigue in RMS: MS fatigue and ambulation move at their own pace
  • Understanding symptoms and their impact on patients with multiple sclerosis: What we can learn from social media
  • Ponesimod in CNS modulates astrocytic genes and protects against limbic fibre demyelination via S1P1-selective modulation
  • A short pause in ponesimod treatment completely restores the ability to mount post-vaccination antibody titres in mice
  • Empowerment of multiple sclerosis patients in treatment decision making
  • Ponesimod demonstrated increased clinical benefit over teriflunomide in early disease subgroup compared with overall population
  • Differences in expected number of clinical management events before and during treatment with sphingosine-1-phosphate receptor modulators for multiple sclerosis
  • Effect of ponesimod compared with teriflunomide on concomitant corticosteroid treatment of relapse in patients with Relapsing forms of multiple sclerosis
  • Analysis and evaluation of ponesimod hepatic safety data

 

Data presented at the 2021 American Psychiatric Nurses Association Annual Conference

Contact us by visiting askjanssenmedinfo.com or by calling 1-800-JANSSEN (1-800-526-7736).

Poster title

  • Acceptability of Long-Acting Injectable Antipsychotic Treatment in Patients with Recent-Onset Schizophrenia from the Disease Recovery Evaluation and Modification (DREaM) Study

 

Data presented at the 7th Congress of the European Academy of Neurology (EAN) 2021

Please contact us directly to request posters presented at this meeting by visiting askjanssenmedinfo.com or by calling 1-800-JANSSEN (1-800-526-7736)

  • Assessment of Composite disability accumulation of Ponesimod relative to Teraflunomide in the OPTUMUM Phase III study
  • Analysis of post-treatment relapse activity in the Phase III OPTIMUM study of Ponesimod compared with Teriflunomide
  • Measuring the symptoms and impacts of fatigue in relapsing multiple sclerosis using a novel disease specific scale

 

Data presented at the 2021 European College of Neuropsychopharmacology Meeting

Virtual congress materials and abstracts from ECNP can be accessed directly at:https://www.ecnp.eu/Congress2021/ECNPcongress/programme/Programme

Abstract

 

Data presented at the 2021 Psych Elevate Annual Meeting

Please refer to the Psych Elevate website directly for oral presentations and posters available for registered attendees at: https://virtual.elevate.psychcongress.com/ or contact us by visiting askjanssenmedinfo.com or by calling 1-800-JANSSEN (1-800-526-7736).

Poster title

  • Effect of Paliperidone Palmitate Versus Oral Antipsychotics on Treatment Failure in Black/African American and Young Adult Subpopulations: A Pooled Analysis of Data from the DREaM and PRIDE Studies

 

Data presented at the 2021 American Society of Clinical Psychopharmacology Annual Meeting

Please refer to the ASCP website directly for oral presentations and posters available for registered attendees at: https://ascp.societyconference.com/v2/ or contact us by visiting askjanssenmedinfo.com or by calling 1-800-JANSSEN (1-800-526-7736).

Poster titles

  • Long-Term Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression: Interim Results of the SUSTAIN-3 Study
  • Intranasal Esketamine Effectively Treats Treatment-Resistant Depression in Adults Regardless of Baseline Irritability
  • Evaluation of Treatment Failure in Real-World Management of Patients with Recent-Onset Schizophrenia from the Disease Recovery Evaluation and Modification (DREaM) Study
  • Efficacy and Safety of Esketamine Nasal Spray by Sex in Patients with Treatment-Resistant Depression: Findings from Randomized, Controlled Trials (encore poster)
  • Characteristics of Real-world Commercially Insured Patients Initiated on Esketamine Nasal Spray, or Other Major Depressive Disorder Therapies in the United States (oral presentation)

 

Data presented at the 2021 Professional Society for Health Economics and Outcomes Research (ISPOR) Annual Meeting

Abstracts and select podium presentations & posters from ISPOR conferences can be accessed directly at https://www.ispor.org/heor-resources/presentations-database/search

Abstracts

 

Data presented at the 2021 American Psychiatric Association Annual Meeting

Please refer to the APA website directly for oral presentations and posters available for registered attendees at: https://apa.onlineeventpro.freeman.com/ or contact us by visiting askjanssenmedinfo.com or by calling 1-800-JANSSEN (1-800-526-7736).

Poster titles

  • Response to Esketamine Nasal Spray in Patients With Major Depressive Disorder and Acute Suicidal Ideation/Behavior Without Evidence of Early Response
  • Efficacy and Safety of Esketamine Nasal Spray by Sex in Patients With Treatment-Resistant Depression: Findings From Randomized, Controlled Trials
  • Characteristics of United States (US) Veterans With Major Depressive Disorder and Their Current Standard of Care: A Real-Word Data Analysis
  • Universal Acute Care Suicide Screening Among the General Population and Individuals With Major Depressive Disorder in a Large Healthcare System
  • Assessing Expert Consensus Around Progression and Mitigation of Cognitive Decline Following Onset of Schizophrenia Disease: A Delphi Method Study
  • Systematic Review of Schizophrenia Clinical Practice Guidelines: Recommendations on Use of Long-Acting Injectable Antipsychotics in the United States
  • A Systematic Literature Review of Schizophrenia Clinical Practice Guidelines: Recommendations on Acute and Maintenance Antipsychotic Treatment
  • Healthcare Resource Utilization and Costs Pre-/Post-Long-Acting Injectable Antipsychotic Use in Commercially Insured Young Adults With Schizophrenia
  • Reductions in Behavioral Healthcare Service Use Among Patients With Schizophrenia Associated With the Covid-19 Pandemic

 

Data presented at the 2021 College of Psychiatric and Neurologic Pharmacists Annual Meeting

Please refer to the CPNP website directly for oral presentations and posters available for registered attendees at: https://cpnp.org/ed/meeting/2021 or contact us by visiting askjanssenmedinfo.com or by calling 1-800-JANSSEN (1-800-526-7736).

Abstracts

 

Data presented at the 2021 Academy of Managed Care Pharmacy Annual Meeting

Virtual congress materials from the AMCP Annual Meeting can be accessed directly at https://amcpannual2021.pathable.co/

Abstracts

 

Data presented at ACTRIMS 2021

Virtual congress materials from ACTRIMS congress can be accessed directly at https://www.abstractsonline.com/pp8/#!/9245.

Abstracts

 

Data presented at Psych Congress 2020

Virtual congress materials from Psych Congress can be accessed directly at https://www.psychcongress.com/posters.

Posters:

 

Data presented at MSVirtual 2020

Virtual congress materials from MSVirtual congress can be accessed directly at https://library.msvirtual2020.org/virtual-library-search?product_id=7.

Posters

  • Effect of oral ponesimod on clinical disease activity and MRI-based outcomes in patients with relapsing multiple sclerosis: Phase 3 OPTIMUM study – P0071
  • Effect on disability measures and MSFC in patients with relapsing multiple sclerosis from the phase 3 ponesimod versus teriflunomide optimum study – P0204
  • Cardiac Safety of Ponesimod in Relapsing Multiple Sclerosis in the Randomized, Active-Controlled, Double-Blind, Parallel-Group Phase 3 OPTIMUM Study -P0194
  • Establishing Meaningful Change Threshold in Multiple Sclerosis related Fatigue on Fatigue Symptoms & Impacts Questionnaire-Relapsing MS (FSIQ-RMS) – P1027
  • Long-term efficacy and safety of ponesimod: Results from randomized phase II core and extension studies in relapsing remitting multiple sclerosis – P0215
  • Treatment Persistency for Patients in a Phase 2 Long-Term Extension Study of Ponesimod – P0177
  • Pharmacokinetic-Pharmacodynamic Models of Lymphocyte Count and Heart Rate Following Ponesimod Dosing in a Phase 2 Study in Multiple Sclerosis Patients – P0224
  • A real-world study characterizing symptoms and impacts of fatigue in US adults with relapsing multiple sclerosis using a novel disease specific scale – P1004
  • Comorbidity and Economic Burdens of Fatigue Among Patients with Relapsing-Remitting Multiple Sclerosis in the United States – P0857
  • Treatment Preferences of Patients with Relapsing Multiple Sclerosis: A Discrete Choice Experiment – P1064
  • Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: A Model-Based Meta-Analysis for Annual Relapse Rate – P0049
  • Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: A Longitudinal Model-Based Meta-Analysis for Confirmed Disability Accumulation – P0048
  • Quality of life and economic burden of fatigue in people with multiple sclerosis: a systematic literature review – P1048